Product Details
| Alternative Name: | Cystatin-3, Neuroendocrine basic polypeptide, CysC |
| |
| MW: | ~13kDa |
| |
| Source: | Isolated from human urine. |
| |
| UniProt ID: | P01034 |
| |
| Formulation: | Lyophilized from 0.02M ammonium bicarbonate buffer. |
| |
| Purity: | ≥95% (SDS-PAGE) |
| |
| Application Notes: | Can be used for the inhibition of cysteine protease activity or of amyloid fibril formation in vitro, in vivo, or in tissue culture. |
| |
| Reconstitution: | Resuspend in water and freeze at -20ºC in aliquots. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Although this is in highly purified form, and the source individual tested negative for all diseases tested, handle this product with all due precautions. |
| |
| Handling: | Aliquot product into individual tubes and freeze at -20 or -70°C. Avoid freeze/thaw cycles. |
| |
| Scientific Background: | Cystatin C is a major member of a large family of endogenous cysteine protease inhibitors found throughout the body. It inhibits proteases such as cathepsin B, H, DPPI, and papain, and is inactivated by neutrophil elastase. It is involved in cancer, rheumatoid arthritis, and other inflammatory diseases, and serves as a marker for renal function. Recently it was shown to bind and inhibit amyloid fibril formation, indicating therapeutic potential for Alzheimer’s disease. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Ameliorate impacts of scopoletin against vancomycin-induced intoxication in rat model through modulation of Keap1-Nrf2/HO-1 and IκBα-P65 NF-κB/P38 MAPK signaling pathways: Molecular study, molecular docking evidence and network pharmacology analysis: M.M. Khalaf, et al.; Int. Immunopharmacol.
102, 108382 (2021),
Abstract;
Attenuation of early brain injury and learning deficits following experimental subarachnoid hemorrhage secondary to Cystatin C: possible involvement of the autophagy pathway: Y. Liu, et al.; Mol. Neurobiol.
49, 1043 (2014),
Abstract;
Detection of cystatin C biomarker for clinical measurement of renal disease by developed ELISA diagnostic kits: R. Jiang, et al.; J. Transl. Med.
12, 205 (2014),
Abstract;
Full Text
Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis: D. Haves-Zburof, et al.; J. Cell. Mol. Med.
15, 2421 (2011),
Abstract;
Full Text
